stonks4u
Sign up free
OCS logo

OCS Oculis Holding AG

NASDAQ Global Market · Biotechnology · Healthcare

$12.94
+0.12 (+0.94%)

Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the man…

Market Cap: $739.77Moculis.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

100
808793100
Aug 10Aug 14

Quote

Day Range
$12.52 – $13.09
52-Week Range
$10.52 – $34.48
Volume
$123.7K
Market Cap
$739.77M
50-Day Avg
$12.15
200-Day Avg
$21.56
Prev Close
$12.82
Open
$12.96

Valuation & Ratios

P/E Ratio
-8.75
EPS
$-1.81
P/B Ratio
4.22
P/S Ratio
0.00
Debt/Equity
0.01
Current Ratio
5.96
Dividend Yield
+0.0%
Gross Margin
+0.0%

Returns & Efficiency

Return on Equity
-48.1%
Return on Assets
-40.0%
FCF Yield
-7.5%
EV/EBITDA
-8.03

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$0.00$-94.51M$-1.81
2024$686.0K$-85.78M$-2.12
2023$0.00$-88.80M$-2.97
2022$0.00$-38.70M$-1.18
2021$0.00$-18.55M$-0.57

Social Signal Score

43
5d
50
1 mentions
—
30d
41
2 mentions
—
60d
41
2 mentions
—
90d
41
2 mentions
—
news: 2

Earnings

Thu, Nov 5(in 3 months)

Consensus estimate $-0.49 per share

2of 7 quarters beat consensus

Typical surprise -11.3% (median, so one quarter with a near-zero estimate can't distort it)

  • Thu, Aug 6$-0.20 vs $-0.48beat
  • Mon, May 11$-0.63 vs $-0.49miss
  • Tue, Mar 3$-0.51 vs $-0.48miss
  • Mon, Nov 10$-0.40 vs $-0.50beat
  • Thu, Aug 21$-0.59 vs $-0.53miss
  • Thu, May 8$-0.77 vs $-0.51miss

Estimates and results for OCS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

OCShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (2)

  • Newsglobenewswire.com·23h ago·Neutral

    Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities ZUG, Switzerland, Aug. 14, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company.

    View source ↗
  • Newsglobenewswire.com·5d ago·Negative

    Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis' Position as an Emerging Leading Neuro-Ophthalmology Company ZUG, Switzerland and BARCELONA, Spain, August 10, 2026 Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, and Accure Therapeutics, S.L. (“Accure”),

    View source ↗